KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $3.9 billion.

  • Vertex Pharmaceuticals' Total Current Liabilities rose 832.07% to $3.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.9 billion, marking a year-over-year increase of 832.07%. This contributed to the annual value of $3.9 billion for FY2025, which is 832.07% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Total Current Liabilities of $3.9 billion as of Q4 2025, which was up 832.07% from $4.5 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Total Current Liabilities registered a high of $4.5 billion during Q3 2025, and its lowest value of $1.8 billion during Q2 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Total Current Liabilities averaged around $3.1 billion, with its median value being $3.4 billion (2023).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Total Current Liabilities crashed by 447.91% in 2021, and later surged by 3919.26% in 2022.
  • Vertex Pharmaceuticals' Total Current Liabilities (Quarter) stood at $2.1 billion in 2021, then increased by 28.02% to $2.7 billion in 2022, then rose by 29.37% to $3.5 billion in 2023, then increased by 0.48% to $3.6 billion in 2024, then grew by 8.32% to $3.9 billion in 2025.
  • Its last three reported values are $3.9 billion in Q4 2025, $4.5 billion for Q3 2025, and $4.1 billion during Q2 2025.